[EN] FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN<br/>[FR] COMPOSÉS DE PYRIMIDINE FUSIONNÉS EN TANT QU'INHIBITEURS DE LA MÉNINE
申请人:[en]BIOMEA FUSION, INC.
公开号:WO2023235618A1
公开(公告)日:2023-12-07
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific covalent inhibitors of a menin or menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds described herein. Methods of using the menin or menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin or menin-MLL interaction.